In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus

Journal of Antibiotics

Volumn 67, Issue 5, 2014, Pages 369-371

  Xu Hong, Yu ^a   Falagas, Matthew E ^b,c,d   Dong, Wang ^e   Karageorgopoulos, Drosos E ^b   De Feng, Lin ^f   Rui, Wang ^e  

^a The 305 Hospital of Chinese PLA   (China)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c HENRY DUNANT HOSPITAL   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CHINESE PLA GENERAL HOSPITAL   (China)

^f Department of Pharmacy Skin Disease Prevention and Control Hospital   (China)

Author keywords

Drug synergism; Fosfomycin; Fractional inhibitory concentration index; Linezolid; Methicillin resistant Staphylococcus aureus; MRSA

Indexed keywords

FOSFOMYCIN; LINEZOLID;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; CHINA; CONTROLLED STUDY; DRUG POTENTIATION; IC 50; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG COMBINATIONS; DRUG SYNERGISM; FOSFOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS;

EID: 84901479100     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2014.5     Document Type: Article

References (41)

1. Lodise, Jr T. P. & McKinnon, P. S. Burden of methicillin-resistant Staphylococcus aureus: Focus on clinical and economic outcomes. Pharmacotherapy 27, 1001-1012 (2007
2. Shorr, A. F. et al. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-Associated pneumonia. Crit. Care 10, R97 (2006
3. Thornsberry, C. Epidemiology of staphylococcal infections-A USA perspective. J. Chemother. 6, 61-65 (1994
4. Vandenbroucke-Grauls, C. Epidemiology of staphylococcal infections-A European perspective. J. Chemother. 6, 67-70 (1994
5. Centers for Disease Control and Prevention (CDC). MRSA among ICU Patients (1995-2004)
6. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32, 470-485 (2004
7. Wang, F., Zhu, D. M., Hu, F. P. & Zhang, Y. Y. Surveillance of bacterial resistance among isolates in Shanghai in 1999. J. Infect. Chemother. 7, 117-120 (2001
8. Ho, P., Yuen, K., Yam, W., Sai-yin Wong, S. & Luk, W. Changing patterns of susceptibilities of blood, urinary and respiratory pathogens in Hong Kong. J. Hosp. Infect. 31, 305-317 (1995
9. Craven, D. E., Kollisch, N. R., Hsieh, C. R., Connolly, Jr M. G. & McCabe, W. R. Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: Comparison with beta-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcus aureus. J. Infect. Dis. 147, 137-143 (1983
10. Sorrell, T. C., Packham, D. R., Shanker, S., Foldes, M. & Munro, R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann. Intern. Med. 97, 344-350 (1982
11. Falagas, M. E., Grammatikos, A. P. & Michalopoulos, A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev. Anti Infect. Ther. 6, 593-600 (2008
12. Shinabarger, D. L. et al. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother. 41, 2132-2136 (1997
13. Zurenko, G. E. et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40, 839-845 (1996
14. Clemett, D. & Markham., A. Linezolid. Drugs 59, 815-827, discussion 828 (2000
15. Diekema, D. I. & Jones., R. N. Oxazolidinones: A review. Drugs 59, 7-16 (2000
16. Gemmell, C. G. Susceptibility of a variety of clinical isolates to linezolid: A European inter-country comparison. J. Antimicrob. Chemother. 48, 47-52 (2001
17. Swaney, S. M., Aoki, H., Ganoza, M. C. & Shinabarger, D. L. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. 42, 3251-3255 (1998
18. Tsiodras, S. et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207-208 (2001
19. Chien, J. W., Kucia, M. L. & Salata, R. A. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin. Infect. Dis. 30, 146-151 (2000
20. Jones, R. N., Ballow, C. H. & Biedenbach, D. J. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagn. Microbiol. Infect. Dis. 40, 59-66 (2001
21. Perry, C. M. & Jarvis., B. Linezolid: A review of its use in the management of serious gram-positive infections. Drugs 61, 525-551 (2001
22. Gee, T. et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother. 45, 1843-1846 (2001
23. Beibei, L. et al. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: Meta-Analysis of randomised controlled trials. Int. J. Antimicrob. Agents 35, 3-12 (2010
24. Forsgren, A. & Walder, M. Antimicrobial activity of fosfomycin in vitro. J. Antimicrob. Chemother. 11, 467-471 (1983
25. Grif, K., Dierich, M. P., Pfaller, K., Miglioli, P. A. & Allerberger, F. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J. Antimicrob. Chemother. 48, 209-217 (2001
26. Falagas, M. E. et al. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. Int. J. Antimicrob. Agents 35, 497-499 (2010
27. Falagas, M. E., Roussos, N., Gkegkes, I. D., Rafailidis, P. I. & Karageorgopoulos, D. E. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: A review of microbiological, animal and clinical studies. Expert Opin. Investig. Drugs 18, 921-944 (2009
28. Morikawa, K., Oseko, F., Morikawa, S. & Sawada, M. Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. Antimicrob. Agents Chemother. 37, 2684-2687 (1993
29. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Nineteenth Informational Supplement. CLSI document M100-S19 (CLSI, Wayne, PA, USA, 2009
30. Moody, J. Synergism testing: Broth microdilution checkerboard and broth macrodilution method. In C. m-b. p. handbook (ed. Isenberg, HD) vol 2nd edn p 1-28 (ASM Press, Washington, DC, USA, 2004
31. Sahuquillo Arce, J. M. et al. In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev. Esp. Quimioter. 19, 252-257 (2006
32. Odds, F. C. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52, 1 (2003
33. Falagas, M. E., Manta, K. G., Ntziora, F. & Vardakas, K. Z. Linezolid for the treatment of patients with endocarditis: A systematic review of the published evidence. J. Antimicrob. Chemother. 58, 273-280 (2006
34. Jang, H. C. et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: Efficacy of linezolid with or without carbapenem. Clin. Infect. Dis. 49, 395-401 (2009
35. Pachon-Ibanez, M. E. et al. Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin. Eur. J. Clin. Microbiol. Infect. Dis. 30, 89-95 (2011
36. Bressler, A. M., Zimmer, S. M., Gilmore, J. L. & Somani, J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet. Infect. Dis. 4, 528-531 (2004
37. Courtieu, A. L., Drugeon, H. & Billaudel, S. Susceptibility to fosfomycin of hospital strains isolated in Nantes (France). Frequency of mutation to resistance. Chemotherapy 23, 25-36 (1977
38. Roussos, N., Karageorgopoulos, D. E., Samonis, G. & Falagas, M. E. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int. J. Antimicrob. Agents 34, 506-515 (2009
39. Grundmann, H., Aires-de-Sousa, M., Boyce, J. & Tiemersma, E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368, 874-885 (2006
40. Moreno, F., Crisp, C., Jorgensen, J. H. & Patterson., J. E. Methicillin-resistant Staphylococcus aureus as a community organism. Clin. Infect. Dis. 21, 1308-1312 (1995
41. Robinson, D. A. et al. Re-emergence of early pandemic Staphylococcus aureus as a community-Acquired meticillin-resistant clone. Lancet 365, 1256-1258 (2005